2008
DOI: 10.1007/s00213-008-1377-3
|View full text |Cite
|
Sign up to set email alerts
|

The incidence of unpleasant dreams after sub-anaesthetic ketamine

Abstract: Ketamine causes unpleasant dreams over the three post-administration nights. This may be evidence of a residual psychotogenic effect that is not found on standard self-report symptomatology measures or a result of disturbed sleep electrophysiology.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
19
0

Year Published

2011
2011
2018
2018

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 35 publications
(19 citation statements)
references
References 95 publications
(91 reference statements)
0
19
0
Order By: Relevance
“…Prior generations of competitive and noncompetitive NMDAR antagonists cause a variety of off-target and on-target adverse effects that prevented clinical development, including motor dysfunction, cognitive impairment, and psychotomimetic effects including hallucinations, paranoia, disorganized thought, and blunted affect (Lees et al, 2000; Sacco et al, 2001; Diener et al, 2002; Rowland 2005; Wood 2005; Muir 2006; Blagrove et al, 2009). Although the GluN2B-selective class of antagonists are better tolerated than competitive antagonists or channel blockers, they are not necessarily free from on-target side effects (Chaperon et al, 2003; DeVry and Jentzsch 2003; Yurkewicz et al, 2005; Nicholson et al, 2007; Preskorn et al, 2008; Nutt et al, 2008).…”
Section: Resultsmentioning
confidence: 99%
“…Prior generations of competitive and noncompetitive NMDAR antagonists cause a variety of off-target and on-target adverse effects that prevented clinical development, including motor dysfunction, cognitive impairment, and psychotomimetic effects including hallucinations, paranoia, disorganized thought, and blunted affect (Lees et al, 2000; Sacco et al, 2001; Diener et al, 2002; Rowland 2005; Wood 2005; Muir 2006; Blagrove et al, 2009). Although the GluN2B-selective class of antagonists are better tolerated than competitive antagonists or channel blockers, they are not necessarily free from on-target side effects (Chaperon et al, 2003; DeVry and Jentzsch 2003; Yurkewicz et al, 2005; Nicholson et al, 2007; Preskorn et al, 2008; Nutt et al, 2008).…”
Section: Resultsmentioning
confidence: 99%
“…The possible reason for our frequent incidence of not achieving loss of consciousness was our relatively low dose of ketamine (0.6 mg/kg) in comparison with other studies, which used 1 to 2 mg/kg. Blagrove et al 3 found that individual differences in the incidence of unpleasant dreams after ketamine administration were significantly associated with retrospective home nightmare frequency, which was an important predictor of the incidence of unpleasant dreams. 9,10 In our study, the STAI, which can affect dream content, was not different between the 2 groups.…”
Section: Discussionmentioning
confidence: 98%
“…We specifically chose ketamine because it shares some traits with rapid eye movement sleep, including cortical activation, increased cholinergic tone, and dream states. 38,16,23,17,24 …”
Section: Discussionmentioning
confidence: 99%